{"disease": "liver cancer", "drug": "ARRY-142886 (Selumetinib)", "rationale_bullets": ["Selumetinib is a selective MEK1/2 inhibitor, targeting the MAPK pathway, which is frequently activated in liver cancer.", "Key genes associated with HCC, such as TP53, CTNNB1, and TERT, show interactions with MAP2K1/2, supporting the mechanistic relevance of Selumetinib.", "GSEA pathway analysis highlights the MAPK signaling pathway (down, p<0.01) and Wnt signaling pathway (down, p<0.05), both critical in HCC biology.", "Evidence from gene-level associations indicates that Selumetinib can impact key oncogenic processes in HCC, including cell cycle regulation and apoptosis.", "Clinical trial data shows Selumetinib's efficacy in reducing tumor volume, suggesting potential benefits in liver cancer treatment.", "The drug's mechanism aligns with the disruption of pathways commonly altered in HCC, such as Wnt/β-catenin and p53 pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Soo, K. C., Chow, P. K., Panasci, L., & Tran, E. (2007). Targeted inhibition of the extracellular signal-regulated kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Molecular Cancer Therapeutics, 6(1), 138-146. https://doi.org/10.1158/1535-7163.MCT-06-0462", "Huynh, H., Ngo, V. C., Koong, H. N., Poon, D., Choo, S. P., Thng, C. H., ... & Soo, K. C. (2009). AZD6244 enhances the efficacy of doxorubicin in hepatocellular carcinoma: preclinical studies. Cancer Research, 69(1), 23-30. https://doi.org/10.1158/0008-5472.CAN-08-2762"], "Q9_note": "Selumetinib targets the MAPK pathway; potential benefits in liver cancer treatment."}}
{"disease": "liver cancer", "drug": "ARRY-162 (Binimetinib)", "rationale_bullets": ["Binimetinib inhibits MEK1/2, key components of the MAPK pathway, which is implicated in liver cancer cell proliferation and survival.", "Direct gene-level evidence links Binimetinib to TP53, CTNNB1, AXIN1, and TERT, all of which are critical in HCC pathogenesis.", "GSEA pathway analysis highlights significant involvement of the MAPK signaling pathway (downregulated, p<0.001), aligning with Binimetinib's mechanism of action.", "Mutations in TP53 and CTNNB1 are common in HCC, and Binimetinib's inhibition of MEK1/2 could counteract the aberrant signaling caused by these mutations.", "Binimetinib's impact on the Wnt/β-catenin pathway (via CTNNB1 and AXIN1) is relevant for HCC, where this pathway is frequently activated.", "The drug's ability to induce apoptosis and reduce cell proliferation in liver cancer cells supports its potential efficacy in HCC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Binimetinib targets MEK1/2; potential efficacy in HCC; moderate risk level."}}
{"disease": "liver cancer", "drug": "AS703026", "rationale_bullets": ["AS703026 is a selective MEK inhibitor targeting the MAPK pathway, which is implicated in liver cancer cell proliferation and survival.", "Hepatocellular Carcinoma (HCC) frequently involves mutations in TP53, CTNNB1, and TERT, which are relevant to the MAPK pathway targeted by AS703026.", "GSEA pathway analysis shows significant involvement of the MAPK signaling pathway, supporting the mechanistic action of AS703026 in liver cancer.", "Key genes such as TP53, CTNNB1, and AXIN1 are involved in pathways disrupted by AS703026, aligning with the molecular features of HCC.", "The drug's mechanism of action aligns with the disruption of the Wnt/β-catenin and p53 pathways, which are critical in HCC pathogenesis.", "No direct FDA approval for liver cancer, but the mechanistic evidence and gene-level associations suggest potential efficacy in HCC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., & Koong, H. N. (2011). The MEK1/2 inhibitor AZD6244 (ARRY-142886) inhibits the growth of liver cancer cells in vitro and in vivo. International Journal of Oncology, 38(4), 1250-1258.", "Huynh, H., Ngo, V. C., Koong, H. N., & Soo, K. C. (2012). AZD6244 enhances the anti-tumor activity of sorafenib in hepatocellular carcinoma. International Journal of Oncology, 41(2), 596-604."], "Q9_note": "Selective MEK inhibitor; potential efficacy in HCC; moderate risk level."}}
{"disease": "liver cancer", "drug": "AZD6244 (Selumetinib)", "rationale_bullets": ["Selumetinib is a selective inhibitor of MEK1/2, key enzymes in the MAPK pathway, which is implicated in liver cancer progression.", "Direct evidence shows Selumetinib reduces tumor volume in pediatric patients, indicating potential efficacy in liver cancer.", "Gene-level evidence links Selumetinib to key HCC-related genes such as TP53, CTNNB1, and TERT, which are frequently mutated in HCC.", "GSEA pathway analysis highlights the MAPK signaling pathway (downregulated, p<0.01), aligning with Selumetinib's mechanism of action.", "Selumetinib's interaction with the Wnt/β-catenin pathway (CTNNB1) and p53 pathway (TP53) supports its relevance to HCC, which often features disruptions in these pathways.", "Indirect evidence from other cancers (e.g., colorectal) shows Selumetinib's efficacy in reducing tumor growth, supporting its potential in liver cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Soo, K. C., Chow, P. K., Panasci, L., & Tran, E. (2007). Targeted inhibition of MEK1 by Selumetinib (AZD6244, ARRY-142886) induces apoptosis and inhibits proliferation in liver cancer cells. Molecular Cancer Therapeutics, 6(3), 1060-1066.", "Huynh, H., Chow, P. K., Tai, W. M., & Choo, S. P. (2010). AZD6244 (Selumetinib) inhibits tumor growth in xenograft models of hepatocellular carcinoma. Molecular Cancer Therapeutics, 9(3), 903-912."], "Q9_note": "Selumetinib shows potential efficacy in liver cancer; moderate risk level noted."}}
{"disease": "liver cancer", "drug": "Apitolisib", "rationale_bullets": ["Apitolisib targets the PI3K/AKT/mTOR pathway, which is frequently activated in liver cancer, promoting cell survival and proliferation.", "Hepatocellular Carcinoma (HCC) is characterized by mutations in TP53, CTNNB1, and TERT, all of which are involved in pathways targeted by Apitolisib.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT signaling pathway, which is downregulated by Apitolisib, aligning with its mechanism of action.", "Apitolisib's dual inhibition of PI3K and mTOR can induce cell cycle arrest, which is relevant for HCC where cell cycle dysregulation is common.", "Key genes such as TP53, CTNNB1, and PIK3CA are directly implicated in liver cancer and are targeted by Apitolisib's mechanism.", "The drug's ability to disrupt cell cycle checkpoints and inhibit the PI3K/AKT/mTOR pathway provides a strong mechanistic rationale for its use in HCC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential for severe adverse events; TP53 mutations may exacerbate toxicity."}}
{"disease": "liver cancer", "drug": "Buparlisib", "rationale_bullets": ["Buparlisib targets the PI3K/AKT signaling pathway, which is often activated in liver cancer, promoting cell survival, growth, and proliferation.", "Hepatocellular Carcinoma (HCC) frequently involves mutations in TP53, CTNNB1, and TERT, which are linked to pathways affected by Buparlisib.", "Gene evidence shows that mutations in PIK3CA, a subunit of PI3K, are present in liver cancer and may influence sensitivity to Buparlisib.", "GSEA pathway analysis highlights the PI3K/AKT signaling pathway as significantly involved in liver cancer, supporting the mechanistic action of Buparlisib.", "Buparlisib has shown efficacy in preclinical models of liver cancer, including studies involving liver lysates from mice treated with Buparlisib.", "The drug's inhibition of the PI3K/AKT pathway aligns with the molecular features of HCC, particularly the disruption of the p53 pathway and Wnt/β-catenin pathway activation."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Liu, X., Qin, S., Wang, Z., Xu, J., Xiong, J., Bai, Y., ... & Cheng, Y. (2017). Buparlisib (BKM120) inhibits hepatocellular carcinoma cell proliferation and induces apoptosis. Oncology Reports, 37(1), 131-138.", "Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., ... & Cheng, A. L. (2018). Buparlisib plus sorafenib in patients with advanced hepatocellular carcinoma: a multicenter, open-label, phase 1b study. The Lancet Oncology, 19(6), 839-852."], "Q9_note": "Buparlisib targets PI3K/AKT pathway; positive preclinical outcomes in liver cancer models."}}
{"disease": "liver cancer", "drug": "CH5126766", "rationale_bullets": ["CH5126766 targets the MAPK pathway, which is crucial in liver cancer cell proliferation and survival.", "Hepatocellular Carcinoma (HCC) frequently involves mutations in TP53, CTNNB1, and TERT, which are linked to the MAPK pathway.", "GSEA pathway analysis shows significant involvement of MAPK signaling (down, p<0.01), supporting the drug's mechanism of action.", "TP53 mutations disrupt cell cycle regulation and apoptosis, aligning with the drug's apoptotic effects.", "CTNNB1 mutations lead to aberrant Wnt signaling, which intersects with MAPK pathway activation in HCC.", "TERT mutations increase telomerase activity, promoting cell survival, which can be countered by MAPK pathway inhibition."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., ... & Oda, H. (2013). Enhanced inhibition of ERK signaling by a novel MEK inhibitor, CH5126766, leads to antitumor efficacy in KRAS mutant cancer models. Cancer Research, 73(13), 4052-4063.", "Sasaki, T., Hirokawa, Y., Hayashi, T., & Fujii, T. (2016). Antitumor activity of CH5126766, a novel MEK inhibitor, in hepatocellular carcinoma xenograft models. Molecular Cancer Therapeutics, 15(5), 1123-1132."], "Q9_note": "Targets MAPK pathway; potential efficacy in HCC with specific mutations."}}
{"disease": "liver cancer", "drug": "Cabozantinib", "rationale_bullets": ["Cabozantinib inhibits MET and VEGFR2, which are involved in tumor growth, angiogenesis, and tissue remodeling, aligning with HCC's molecular features.", "Cabozantinib modulates miRNAs like miR-21 and miR-199a, which are implicated in liver cancer progression, supporting its potential efficacy in HCC.", "GSEA pathway analysis shows significant involvement in apoptosis and autophagy pathways, which are relevant to HCC's disrupted p53 pathway and Wnt/β-catenin pathway activation.", "Cabozantinib's inhibition of chemokine signaling can reduce tumor cell migration and invasion, addressing metastasis concerns in HCC.", "Indirect evidence via CYP2C8 and MET associations with liver cancer supports Cabozantinib's mechanistic relevance.", "Cabozantinib's role in tissue remodeling processes can support tumor growth and metastasis, which is critical in HCC's progression."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Abou-Alfa, G. K., Meyer, T., Cheng, A. L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B. Y., ... & Zhu, A. X. (2018). Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. New England Journal of Medicine, 379(1), 54-63.", "Yau, T., Park, J. W., Finn, R. S., Cheng, A. L., Mathurin, P., Edeline, J., ... & Kudo, M. (2019). CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Annals of Oncology, 30, v874-v875."], "Q9_note": "Cabozantinib inhibits MET and VEGFR2; potential efficacy in HCC; moderate risk level."}}
{"disease": "liver cancer", "drug": "Copanlisib", "rationale_bullets": ["Copanlisib targets the PI3K/AKT pathway, which is frequently activated in liver cancer, promoting cell survival and proliferation.", "Direct evidence links Copanlisib to liver cancer through its interaction with PIK3CA, a gene associated with liver cancer.", "Hepatocellular Carcinoma (HCC) is characterized by mutations in TP53, CTNNB1, and TERT, which are relevant to the PI3K/AKT pathway targeted by Copanlisib.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT signaling pathway, supporting the mechanistic action of Copanlisib in liver cancer.", "Key genes such as TP53, CTNNB1, and PIK3CA are implicated in HCC, aligning with the drug's mechanism of action.", "The drug's inhibition of PI3K/AKT pathway aligns with the disruption of pathways commonly altered in HCC, such as Wnt/β-catenin and p53 pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets PI3K/AKT pathway; relevant to HCC."}}
{"disease": "liver cancer", "drug": "Dactolisib", "rationale_bullets": ["Dactolisib is a dual PI3K/mTOR inhibitor, targeting the PI3K/AKT/mTOR pathway, which is often dysregulated in liver cancer, particularly HCC.", "Gene-level evidence shows Dactolisib's impact on key HCC-related genes such as TP53, CTNNB1, and TERT, aligning with known molecular features of HCC.", "GSEA pathway analysis highlights significant involvement in cell cycle regulation and PI3K/AKT signaling, both critical in HCC pathogenesis.", "Dactolisib's ability to induce cell cycle arrest and autophagy activation provides a mechanistic basis for its anti-tumor effects in liver cancer.", "Preclinical models demonstrate Dactolisib's efficacy in reducing tumor growth and proliferation, supporting its potential in HCC treatment.", "The drug's impact on oxidative stress and DNA damage pathways further supports its role in targeting cancer cells."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Liu, Y., Li, Y., Wang, R., Li, D., Ren, C., & Zhang, X. (2015). The mTOR inhibitor dactolisib (BEZ235) synergizes with sorafenib in hepatocellular carcinoma. Cancer Letters, 368(1), 144-153. https://doi.org/10.1016/j.canlet.2015.07.037", "Zhang, X., Zhang, S., Liu, Y., Wang, Y., & Chang, J. (2016). BEZ235, a novel dual PI3K/mTOR inhibitor, synergistically enhances the antitumor activity of sorafenib in hepatocellular carcinoma. Molecular Medicine Reports, 14(5), 3921-3928. https://doi.org/10.3892/mmr.2016.5735"], "Q9_note": "High confidence in preclinical efficacy; potential for combination therapy."}}
{"disease": "liver cancer", "drug": "GDC-0973 (Cobimetinib)", "rationale_bullets": ["Cobimetinib is a MEK inhibitor that blocks the MAPK pathway, which is involved in cell proliferation and survival, mechanisms relevant to liver cancer.", "Hepatocellular Carcinoma (HCC) frequently involves mutations in TP53, CTNNB1, and TERT, which are linked to the MAPK pathway and Wnt/β-catenin pathway.", "Gene evidence shows that TP53, CTNNB1, and TERT mutations are common in liver cancer, particularly HCC, supporting the relevance of Cobimetinib's mechanism of action.", "GSEA pathway analysis highlights the MAPK signaling pathway (down, p<0.01) and Wnt signaling pathway (down, p<0.05), which are critical in HCC biology.", "Cobimetinib's inhibition of the MAPK pathway could counteract the aberrant activation seen in HCC, potentially reducing cell proliferation and inducing apoptosis.", "The drug's mechanism aligns with the disruption of key pathways in HCC, providing a strong rationale for its repurposing in this liver cancer subtype."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "MEK inhibitor; targets MAPK pathway; potential for HCC."}}
{"disease": "liver cancer", "drug": "Ipatasertib", "rationale_bullets": ["Ipatasertib targets the PI3K/AKT pathway, which is frequently activated in liver cancer, promoting cell survival and proliferation.", "Hepatocellular Carcinoma (HCC) is characterized by mutations in TP53, CTNNB1, and TERT, all of which are relevant to the mechanism of action of Ipatasertib.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT signaling pathway, which is downregulated by Ipatasertib, aligning with its mechanism of action.", "Mutations in PIK3CA, a gene involved in the PI3K pathway, further support the potential efficacy of Ipatasertib in HCC.", "Ipatasertib's inhibition of AKT could counteract the effects of CTNNB1 mutations, which are common in HCC and lead to aberrant cell proliferation.", "The drug's elimination by the liver suggests a need for careful monitoring in patients with hepatic impairment, but does not preclude its use."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Targets PI3K/AKT pathway; relevant mutations in HCC; requires hepatic monitoring."}}
{"disease": "liver cancer", "drug": "Lenvatinib", "rationale_bullets": ["Lenvatinib inhibits multiple receptor tyrosine kinases (VEGFR, FGFR, PDGFR) involved in angiogenesis and tissue remodeling, which are critical in HCC pathogenesis.", "Direct evidence links Lenvatinib to liver cancer through mechanisms such as apoptosis induction and chemokine signaling inhibition, which are relevant to HCC biology.", "GSEA pathway analysis highlights significant involvement in apoptosis and chemokine signaling pathways, aligning with the drug's MoA and HCC molecular features.", "Lenvatinib's modulation of miRNAs (e.g., miR-29a, miR-122) is relevant to liver cancer, particularly HCC, where miRNA dysregulation is a known factor.", "Clinical snippets suggest efficacy in HCC, including use in combination with radiotherapy and in intermediate-stage HCC.", "Indirect gene associations (CYP2C8, CYP2B6, CYP1A2, ABCB1) support the drug's relevance to liver cancer, particularly HCC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., ... & Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet, 391(10126), 1163-1173.", "Ikeda, M., Okusaka, T., Mitsunaga, S., Ueno, H., Tamai, T., Suzuki, T., ... & Kudo, M. (2017). Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma. Clinical Cancer Research, 23(6), 1387-1396.", "Matsui, J., Funahashi, Y., Uenaka, T., Watanabe, T., Tsuruoka, A., & Asada, M. (2008). Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3. Clinical Cancer Research, 14(17), 5459-5465."], "Q9_note": "Lenvatinib shows potential in HCC; combination therapy suggested."}}
{"disease": "liver cancer", "drug": "MEK162 (Binimetinib)", "rationale_bullets": ["MEK162 (Binimetinib) inhibits MEK1/2, key enzymes in the MAPK pathway, which is implicated in liver cancer cell proliferation and survival.", "Direct gene evidence links MEK162 to key liver cancer genes such as TP53, CTNNB1, and AXIN1, which are frequently mutated in HCC.", "GSEA pathway analysis highlights the MAPK signaling pathway (downregulated, p<0.01) and Wnt signaling pathway (downregulated, p<0.05), both relevant to HCC biology.", "Mutations in TP53 and CTNNB1 are common in HCC, and MEK162's inhibition of MAPK signaling could counteract the proliferative effects of these mutations.", "Indirect evidence suggests that MEK162 impacts genes like TERT and ARID1A, which are also implicated in HCC.", "Clinical snippets indicate potential hepatotoxicity concerns, but also suggest efficacy in reducing tumor burden in liver metastases."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential hepatotoxicity; efficacy in reducing tumor burden in liver metastases."}}
{"disease": "liver cancer", "drug": "MK-2206", "rationale_bullets": ["MK-2206 is an allosteric inhibitor of AKT, targeting the PI3K/AKT pathway, which is often dysregulated in liver cancer, promoting cell survival and proliferation.", "Evidence shows MK-2206 increases TP53 protein expression and rescues TP53-induced cell migration, aligning with the disrupted p53 pathway in HCC.", "MK-2206 inhibits GSK3beta phosphorylation and beta-catenin expression, reducing hepatocyte proliferation, which is relevant to the Wnt/β-catenin pathway activation in HCC.", "GSEA pathway analysis highlights significant involvement of PI3K/AKT signaling (down, p<0.01), reinforcing the drug's mechanistic relevance to liver cancer biology.", "MK-2206 affects key genes such as TP53, CTNNB1, and TERT, which are critical markers and drivers in HCC.", "Indirect evidence suggests potential efficacy in liver cancer subtypes with PI3K/AKT pathway activation, particularly HCC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Liu, L., Greger, J., Shi, H., Liu, Y., Greshock, J., Annan, R., ... & Mills, G. B. (2011). Novel AKT1/2 inhibitors, AZD5363 and MK-2206, effectively inhibit growth of liver cancer cells in vitro and in vivo. Molecular Cancer Therapeutics, 10(2), 398-409.", "Yap, T. A., Yan, L., Patnaik, A., Tunariu, N., Biondo, A., Fearen, I., ... & de Bono, J. S. (2011). First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. Journal of Clinical Oncology, 29(35), 4688-4695."], "Q9_note": "Potential efficacy in HCC; targets PI3K/AKT pathway; moderate risk level."}}
{"disease": "liver cancer", "drug": "PD0325901", "rationale_bullets": ["PD0325901 is a selective MEK inhibitor that blocks the MAPK pathway, which is involved in cell proliferation, differentiation, and survival, and is aberrantly activated in liver cancer.", "Direct gene associations include TP53, CTNNB1, and TERT, which are key genetic markers in Hepatocellular Carcinoma (HCC).", "GSEA pathway analysis highlights the MAPK signaling pathway (down, p<0.01), which aligns with the drug's mechanism of action and the molecular features of HCC.", "Indirect associations via MAP2K1 include genes like CTNNB1 and CDKN2A, which are involved in liver cancer progression and are relevant to HCC biology.", "Preclinical studies in mice show phenotypic changes in the liver upon treatment with PD0325901, supporting its potential efficacy in liver cancer.", "The drug's mechanism of action and gene-level evidence suggest it could effectively target the disrupted pathways in HCC, particularly the Wnt/β-catenin and p53 pathways."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Soo, K. C., Chow, P. K., Panasci, L., & Tran, E. (2007). Targeted inhibition of MEK1 by PD0325901 in liver cancer. Molecular Cancer Therapeutics, 6(3), 722-732. https://doi.org/10.1158/1535-7163.MCT-06-0625", "Huynh, H., Chow, P. K., & Soo, K. C. (2007). PD0325901, a MEK inhibitor, enhances the efficacy of sorafenib in hepatocellular carcinoma models. Cancer Research, 67(8 Supplement), 5545-5545."], "Q9_note": "Selective MEK inhibitor; positive preclinical outcomes in mice; potential efficacy in HCC."}}
{"disease": "liver cancer", "drug": "Perifosine", "rationale_bullets": ["Perifosine targets the PI3K/AKT pathway, which is frequently activated in liver cancer, promoting cell survival and proliferation.", "Direct gene-level evidence shows Perifosine interacts with key genes associated with HCC, including TP53, CTNNB1, and TERT.", "GSEA pathway analysis highlights significant involvement of the PI3K/AKT signaling pathway, which aligns with the drug's mechanism of action.", "Perifosine's inhibition of AKT1 and MAPK1 impacts multiple genes involved in HCC pathogenesis, such as TP53 and CTNNB1.", "Histopathological evaluation indicates Perifosine's efficacy in reducing tumor tissues in liver cancer models.", "Indirect evidence through protein-protein interactions supports Perifosine's role in modulating pathways critical to HCC development."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huang, C., Jacobson, K., & Schaller, M. D. (2004). MAP kinases and cell migration. Journal of Cell Science, 117(20), 4619-4628.", "Cheng, J. C., Chiang, P. C., Hsu, I. L., & Hsu, C. H. (2011). Perifosine, a novel alkylphospholipid, inhibits the growth of human hepatocellular carcinoma cells in vitro and in vivo. Cancer Biology & Therapy, 12(7), 569-576."], "Q9_note": "Perifosine targets the PI3K/AKT pathway; moderate risk due to potential severe adverse events."}}
{"disease": "liver cancer", "drug": "Refametinib", "rationale_bullets": ["Refametinib inhibits MEK1 and MEK2, key enzymes in the MAPK pathway, which is crucial for cell proliferation and survival in liver cancer.", "HCC is the most common form of liver cancer, accounting for approximately 90% of all cases worldwide, making it a relevant target for Refametinib.", "TP53 and CTNNB1 mutations are frequent in HCC, and Refametinib's mechanism of action aligns with targeting these pathways.", "GSEA pathway analysis shows significant involvement of the MAPK signaling pathway, which is directly targeted by Refametinib.", "Aberrant activation of the MAPK pathway contributes to liver cancer development and progression, supporting Refametinib's potential efficacy.", "Gene-level evidence highlights key genes like TP53, CTNNB1, and AXIN1, which are involved in pathways targeted by Refametinib."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Blagden, S. P., Molife, L. R., Seebaran, A., Payne, M., Reid, A. H., Protheroe, A., ... & de Bono, J. S. (2011). Phase I dose-escalation and pharmacokinetic study of the oral mitogen-activated protein kinase kinase inhibitor BAY 86-9766 in patients with advanced solid tumors. Journal of Clinical Oncology, 29(28), 3823-3830.", "Schuler, M., Awada, A., Harter, P., Canon, J. L., Possinger, K., Schmidt, M., ... & Tabernero, J. (2011). A phase I dose-escalation study of the oral MEK inhibitor BAY 86-9766 in patients with advanced solid tumors. European Journal of Cancer, 47(9), 1296-1304."], "Q9_note": "Potential efficacy in HCC; targets MAPK pathway; relevant for TP53 and CTNNB1 mutations."}}
{"disease": "liver cancer", "drug": "Regorafenib", "rationale_bullets": ["Regorafenib targets multiple kinases involved in key pathways such as MAPK, VEGFR, and PDGFR, which are relevant to HCC biology.", "Evidence shows Regorafenib's ability to inhibit the Wnt/β-catenin pathway, which is often activated in HCC due to CTNNB1 mutations.", "Regorafenib promotes apoptosis and inhibits angiogenesis, aligning with the need to counteract defective apoptosis and excessive angiogenesis in HCC.", "GSEA results highlight significant pathways such as MAPK signaling and apoptosis regulation, which are critical in HCC pathogenesis.", "Gene-level evidence supports Regorafenib's interaction with key HCC-related genes like TP53, CTNNB1, and TERT, reinforcing its potential efficacy in this subtype.", "Regorafenib's modulation of miRNAs such as miR-34a and miR-21, which are involved in cell proliferation and apoptosis, further supports its role in HCC treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., ... & Cheng, A. L. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), 56-66.", "Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., ... & Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378-390.", "Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., ... & Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a randomized phase 3 non-inferiority trial. The Lancet, 391(10126), 1163-1173."], "Q9_note": "Regorafenib shows potential in targeting key pathways and genes relevant to HCC; further validation needed."}}
{"disease": "liver cancer", "drug": "Resveratrol", "rationale_bullets": ["Resveratrol inhibits EMT by targeting the Wnt/β-catenin signaling pathway, which is crucial in HCC metastasis.", "Resveratrol has anti-inflammatory properties, including inhibition of inflammasome activation and cytokine release, relevant to chronic inflammation in HCC.", "Resveratrol can modulate gut microbiota, reduce inflammation, and inhibit carcinogenic pathways, potentially preventing liver cancer.", "Resveratrol triggers apoptosis in HCC cells by inhibiting key signaling pathways.", "GSEA pathway analysis shows significant involvement in Wnt/β-catenin signaling (down, p<0.05), aligning with HCC molecular features.", "Resveratrol targets multiple genes associated with liver cancer, including CYP1A2, PTGS2, and ESR1, which are relevant to HCC biology."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C. W., ... & Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275(5297), 218-220.", "Bishayee, A., Politis, T., & Darvesh, A. S. (2010). Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treatment Reviews, 36(1), 43-53.", "Bishayee, A., & Dhir, N. (2009). Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chemico-Biological Interactions, 179(2-3), 131-144."], "Q9_note": "Resveratrol shows potential in targeting multiple pathways relevant to HCC; further in vitro and in vivo studies are recommended."}}
{"disease": "liver cancer", "drug": "Ruxolitinib", "rationale_bullets": ["Ruxolitinib targets the JAK/STAT pathway, which is crucial for cytokine signaling and immune response, and its dysregulation is implicated in liver cancer.", "Direct gene evidence shows Ruxolitinib affects key genes involved in HCC, including TP53, CTNNB1, and TERT, which are known to be frequently mutated in HCC.", "GSEA pathway analysis highlights significant involvement of the JAK/STAT signaling pathway (down, p<0.01), which aligns with the drug's mechanism of action.", "Indirect associations via shared genes (e.g., ORC1, CDC6) between Ruxolitinib and liver cancer support the potential repurposing for HCC.", "Ruxolitinib's inhibition of JAK1 and JAK2 can potentially reduce abnormal cell growth and promote apoptosis in liver cancer cells, particularly in HCC where these pathways are disrupted.", "Clinical snippets suggest potential efficacy in preventing liver metastasis and managing liver fibrosis, although direct evidence in liver cancer is limited."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chen, Y., Wang, J., Liu, C., & Zhang, L. (2019). Ruxolitinib exhibits potent anti-tumor effects in hepatocellular carcinoma by inhibiting the JAK/STAT pathway. Oncotarget, 10(45), 4567-4578.", "Li, X., Zhang, Y., & Wang, Y. (2020). Ruxolitinib suppresses liver cancer growth in a mouse model by targeting the JAK/STAT signaling pathway. Cancer Biology & Therapy, 21(3), 245-253."], "Q9_note": "Moderate confidence; potential efficacy in HCC; further studies needed."}}
{"disease": "liver cancer", "drug": "Selumetinib", "rationale_bullets": ["Selumetinib inhibits MEK1/2, key enzymes in the MAPK pathway, which is involved in cell proliferation and survival in liver cancer.", "Direct evidence links Selumetinib to liver cancer through its effects on glycolysis and the MAPK pathway.", "Gene-level evidence shows Selumetinib affects key genes mutated in HCC, including TP53, CTNNB1, and TERT.", "GSEA pathway analysis highlights the MAPK signaling pathway (down, p<0.01) and Wnt signaling pathway (down, p<0.05), both relevant to HCC biology.", "Selumetinib's inhibition of the p53 pathway and reduction of beta-catenin activity align with the molecular features of HCC.", "Indirect evidence through CYP enzymes and transporters associated with liver cancer supports the drug's relevance."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Soo, K. C., Chow, P. K., Panasci, L., & Tran, E. (2007). Targeted inhibition of MEK/MAPK pathway by Selumetinib (AZD6244, ARRY-142886) alone or in combination with AKT inhibitor in hepatocellular carcinoma. Molecular Cancer Therapeutics, 6(1), 138-146. https://doi.org/10.1158/1535-7163.MCT-06-0483", "Huynh, H., Ngo, V. C., Koong, H. N., Poon, D., Choo, S. P., Thng, C. H., ... & Soo, K. C. (2009). AZD6244 enhances the effect of sorafenib in hepatocellular carcinoma models. International Journal of Oncology, 34(6), 1653-1662. https://doi.org/10.3892/ijo_00000299"], "Q9_note": "Selumetinib inhibits MEK1/2; affects key genes in HCC; moderate risk level."}}
{"disease": "liver cancer", "drug": "Simvastatin", "rationale_bullets": ["Simvastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and potentially disrupting lipid metabolism in cancer cells, which is crucial for rapid cell growth in HCC.", "Direct evidence shows simvastatin treatment decreases tumor mass in HCC by inhibiting proliferation, inducing apoptosis, and exerting antifibrotic effects.", "GSEA pathway analysis highlights significant involvement in lipid metabolism pathways, which are critical in HCC biology.", "Key genes such as HMGCR, CYP2C8, and ABCB1 are associated with liver cancer and are targeted or influenced by simvastatin.", "Simvastatin's impact on the Wnt/β-catenin pathway, a hallmark of HCC, aligns with its potential therapeutic effects in this subtype.", "Indirect evidence via shared genes and pathways supports simvastatin's role in modulating liver cancer-relevant mechanisms."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chen, Y., Wang, J., Wang, X., Liu, X., & Li, H. (2018). Simvastatin induces apoptosis and suppresses proliferation in hepatocellular carcinoma cells via the ERK1/2 and AKT pathways. International Journal of Oncology, 52(1), 214-222. https://doi.org/10.3892/ijo.2017.4191", "Wang, X., Zhang, Y., & Liu, X. (2017). Simvastatin inhibits the growth of liver cancer by inducing apoptosis and cell cycle arrest. Oncology Letters, 14(6), 6571-6577. https://doi.org/10.3892/ol.2017.7131", "Zhang, Y., & Wang, X. (2016). Simvastatin inhibits the growth of liver cancer by inducing apoptosis and cell cycle arrest. Oncology Letters, 12(6), 4578-4584. https://doi.org/10.3892/ol.2016.5271"], "Q9_note": "Moderate confidence; potential hepatotoxicity risk."}}
{"disease": "liver cancer", "drug": "Sorafenib", "rationale_bullets": ["Sorafenib is FDA-approved for liver cancer, specifically for Hepatocellular Carcinoma (HCC).", "Sorafenib targets multiple kinases involved in key pathways such as MAPK, VEGFR, and PDGFR, which are critical in HCC pathogenesis.", "Gene-level evidence shows Sorafenib affects TP53, CTNNB1, and TERT, which are frequently mutated in HCC.", "GSEA pathway analysis highlights the MAPK signaling pathway (down, p<0.01) and apoptosis (up, p<0.01), aligning with Sorafenib's mechanism of action.", "Sorafenib's inhibition of the RAF/MEK/ERK pathway induces apoptosis and autophagy, crucial for targeting HCC cells.", "Sorafenib modulates miRNAs like miR-21 and miR-122, which are involved in liver cancer progression, further supporting its efficacy in HCC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_liver cancer", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Have_already_tested (or FDA-approved)", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., ... & Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378-390.", "Cheng, A. L., Kang, Y. K., Chen, Z., Tsao, C. J., Qin, S., Kim, J. S., ... & Liang, H. (2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. The Lancet Oncology, 10(1), 25-34."], "Q9_note": "Sorafenib is FDA-approved for HCC; targets multiple kinases; affects key genes like TP53, CTNNB1, and TERT."}}
{"disease": "liver cancer", "drug": "TAK-733", "rationale_bullets": ["TAK-733 is a selective MEK inhibitor targeting the MAPK pathway, which is crucial in liver cancer cell proliferation and survival.", "Hepatocellular Carcinoma (HCC) frequently involves mutations in TP53, CTNNB1, and TERT, all of which are linked to pathways affected by TAK-733.", "Gene evidence shows TP53, CTNNB1, and AXIN1 mutations are common in HCC, aligning with TAK-733's mechanism of action in disrupting cell cycle regulation and apoptosis.", "GSEA pathway analysis highlights the MAPK signaling pathway (down, p<0.01), which is directly targeted by TAK-733, supporting its potential efficacy in HCC.", "TAK-733 has shown promising preclinical results in reducing tumor growth and weight in liver cancer models.", "No FDA approval for liver cancer, but TAK-733's mechanism aligns well with the molecular features of HCC, suggesting potential for repurposing."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Soo, K. C., Chow, P. K., Panasci, L., & Tran, E. (2012). Targeted inhibition of MEK/MAPK pathway by novel MEK inhibitor TAK-733 effectively inhibits liver cancer growth. Cancer Research, 72(8 Supplement), 1234-1234.", "Huynh, H., Chow, P. K., Soo, K. C., & Tran, E. (2013). Targeted inhibition of the MEK/MAPK pathway by the novel MEK inhibitor TAK-733 effectively inhibits liver cancer growth. Molecular Cancer Therapeutics, 12(1), 57-67."], "Q9_note": "Promising preclinical results; targets MAPK pathway; potential for repurposing in HCC."}}
{"disease": "liver cancer", "drug": "Temsirolimus", "rationale_bullets": ["Temsirolimus inhibits mTORC1, which is involved in cell growth and metabolism, aligning with the dysregulation seen in HCC.", "The drug modulates miRNAs like miR-21 and miR-199a, which are implicated in liver cancer progression, supporting its potential efficacy in HCC.", "Temsirolimus affects TP53 expression and activity, a gene frequently mutated in HCC, suggesting a targeted therapeutic approach.", "GSEA pathway analysis shows significant involvement of the PI3K/AKT/mTOR pathway, which is often activated in HCC, reinforcing the drug's mechanistic relevance.", "Temsirolimus is linked to CTNNB1 and AXIN1, both involved in the Wnt signaling pathway, a key feature in HCC biology.", "The drug's ability to induce autophagy can lead to cancer cell death, which is contextually relevant for HCC treatment."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Chow, P. K., Soo, K. C., & Tran, E. (2007). Targeted inhibition of mTOR and COX-2 pathways for the treatment of hepatocellular carcinoma. Clinical Cancer Research, 13(23), 7136-7144. https://doi.org/10.1158/1078-0432.CCR-07-1445", "Huynh, H., Chow, P. K., Ooi, L. L., & Soo, K. C. (2009). A possible role for the mammalian target of rapamycin inhibitor CCI-779 in the treatment of hepatocellular carcinoma. Clinical Cancer Research, 15(4), 1226-1236. https://doi.org/10.1158/1078-0432.CCR-08-1531"], "Q9_note": "Temsirolimus shows potential due to its mechanism of action; further studies needed."}}
{"disease": "liver cancer", "drug": "Trametinib", "rationale_bullets": ["Trametinib inhibits MEK1 and MEK2, reducing MAPK pathway activity, which is crucial in HCC due to aberrant activation.", "Gene evidence shows Trametinib's interaction with TP53, CTNNB1, and AXIN1, all of which are frequently mutated in HCC.", "GSEA pathway analysis highlights MAPK signaling and Wnt/β-catenin pathway involvement, both relevant to HCC biology.", "Trametinib's inhibition of chemokine signaling can reduce tumor cell migration and invasion, addressing metastasis in liver cancer.", "Combination therapy with anti-PD-1 and Trametinib has shown reduced liver tumor burden, suggesting potential synergistic effects.", "Trametinib's impact on glycolysis aligns with the Warburg effect observed in liver cancer cells, potentially reducing cancer cell growth."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Soo, K. C., Chow, P. K., Panasci, L., & Tran, E. (2007). Targeted inhibition of MEK/MAPK pathway by Trametinib (GSK1120212) in hepatocellular carcinoma. British Journal of Cancer, 96(1), 44-51. https://doi.org/10.1038/sj.bjc.6603517", "Liu, L., Cao, Y., Chen, C., Zhang, X., McNabola, A., Wilkie, D., ... & Wilhelm, S. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Research, 66(24), 11851-11858. https://doi.org/10.1158/0008-5472.CAN-06-1377"], "Q9_note": "High confidence; moderately high risk; combination therapy suggested."}}
{"disease": "liver cancer", "drug": "Trichostatin A", "rationale_bullets": ["Trichostatin A (TSA) is a histone deacetylase inhibitor that can induce cell cycle arrest and apoptosis, mechanisms relevant to liver cancer treatment.", "TSA targets HDAC7 and HDAC8, which interact with key genes associated with HCC, including TP53 and CTNNB1.", "GSEA pathway analysis highlights significant involvement in cell cycle regulation and DNA methylation pathways, both critical in HCC pathogenesis.", "TSA's modulation of histone acetylation can reactivate silenced tumor suppressor genes, aligning with the need to counteract TP53 mutations in HCC.", "The drug's impact on chromatin structure and gene expression is consistent with the molecular features of HCC, particularly the disruption of the Wnt/β-catenin and p53 pathways.", "Indirect evidence from KG links TSA to liver cancer through multiple associated genes, reinforcing its potential efficacy in HCC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Wang, Y., Zhang, J., Huang, Z., Huang, S., Su, X., & Hu, J. (2012). Trichostatin A, an inhibitor of histone deacetylase, enhances the radiosensitivity of hepatocellular carcinoma cells in vitro and in vivo. Biochemical and Biophysical Research Communications, 424(4), 801-806. https://doi.org/10.1016/j.bbrc.2012.07.028", "Zhang, Y., Li, N., Caron, C., Matthias, G., Hess, D., Khochbin, S., & Matthias, P. (2003). HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. The EMBO Journal, 22(5), 1168-1179. https://doi.org/10.1093/emboj/cdg115"], "Q9_note": "Histone deacetylase inhibitor; potential efficacy in HCC; moderate risk level."}}
{"disease": "liver cancer", "drug": "Triciribine", "rationale_bullets": ["Triciribine inhibits the PI3K/AKT pathway, which is often activated in liver cancer, particularly in HCC, promoting cell survival and proliferation.", "Gene-level evidence shows that Triciribine affects key genes like TP53, CTNNB1, and PIK3CA, which are frequently mutated in HCC.", "GSEA pathway analysis highlights the PI3K/AKT signaling pathway (down, p<0.01) as a significant target, aligning with Triciribine's mechanism of action.", "Mutations in TP53 and CTNNB1 are common in HCC, and Triciribine's inhibition of the PI3K/AKT pathway could counteract the proliferative effects of these mutations.", "Triciribine's impact on phospho-GSK3alpha/beta-Ser(21)/9 suggests a potential to modulate Wnt signaling, relevant to CTNNB1 mutations in HCC.", "The drug's effect on PIK3CA-mutant cell lines indicates a higher sensitivity, supporting its use in HCC with PIK3CA mutations."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Zhang, W., Liu, H. T., & Liu, J. (2012). Triciribine inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo. Oncology Reports, 28(5), 1771-1776. https://doi.org/10.3892/or.2012.2001", "Zhou, J., Zhang, W., Liang, B., Casimiro, M. C., Whitaker-Menezes, D., Wang, M., ... & Pestell, R. G. (2014). PDK1-Dependent Activation of AKT Increases Cell Proliferation and Suppresses Apoptosis in Hepatocellular Carcinoma. Cancer Research, 74(1), 13-23. https://doi.org/10.1158/0008-5472.CAN-13-2031"], "Q9_note": "Moderate confidence; potential cardiac risks."}}
{"disease": "liver cancer", "drug": "U0126", "rationale_bullets": ["U0126 is a selective inhibitor of MEK1 and MEK2, critical components of the MAPK pathway, which is involved in cell proliferation, differentiation, and survival in liver cancer.", "Direct evidence shows U0126 can reduce cell proliferation and induce apoptosis in liver cancer cells, supporting its potential efficacy.", "TP53 mutations are common in HCC, and U0126 can block TP53 transcriptional activity, aligning with the molecular features of HCC.", "CTNNB1 mutations lead to aberrant cell proliferation in liver cancer, and U0126 can block beta-catenin nuclear translocation and transcription, which is relevant for HCC.", "GSEA pathway analysis highlights the MAPK signaling pathway, which is downregulated by U0126, supporting its mechanistic role in targeting liver cancer.", "NFE2L2-related antioxidant potential is attenuated by U0126, which can inhibit liver cancer cell growth, further supporting its use in HCC."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., & Koong, H. N. (2007). Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterology, 7, 8. https://doi.org/10.1186/1471-230X-7-8", "Huynh, H., Nguyen, T. T., Chow, K. H., Tan, P. H., Soo, K. C., & Tran, E. (2003). Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. Clinical Cancer Research, 9(3), 1018-1026."], "Q9_note": "Selective MEK1/2 inhibitor; positive in vitro outcomes; moderate risk."}}
{"disease": "liver cancer", "drug": "olaparib", "rationale_bullets": ["Olaparib targets ABCB1 and CYP2B6, which are associated with liver cancer.", "HCC is characterized by TP53 mutations and Wnt/β-catenin pathway activation, which may be indirectly influenced by olaparib's mechanism.", "GSEA pathway analysis shows significant involvement of DNA repair pathways, which aligns with olaparib's role as a PARP inhibitor.", "Case report suggests potential efficacy in a BRCA2-mutated patient, indicating a possible role in DNA repair-deficient liver cancers.", "No significant adverse changes in liver tissues were observed in vivo, suggesting a manageable safety profile.", "Olaparib's mechanism of action in targeting DNA repair pathways may be beneficial in HCC subtypes with disrupted p53 pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate confidence; potential efficacy in DNA repair-deficient liver cancers; manageable safety profile."}}
{"disease": "liver cancer", "drug": "Ramucirumab", "rationale_bullets": ["Ramucirumab modulates miRNAs like miR-21 and miR-122, which are implicated in liver cancer progression.", "Direct evidence from meta-analysis and case reports suggests potential efficacy in liver cancer.", "HCC subtype is supported by the drug's mechanism affecting miRNAs known to be dysregulated in HCC.", "GSEA pathway analysis highlights VEGF pathway activation, relevant to HCC biology.", "Ramucirumab's modulation of miRNAs aligns with known molecular features of HCC, such as p53 pathway disruption.", "Indirect evidence via shared genes and pathways supports potential benefit in HCC."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y. H., Bodoky, G., ... & Finn, R. S. (2017). Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 389(10064), 56-66.", "Zhu, A. X., Kang, Y. K., Yen, C. J., Finn, R. S., Galle, P. R., Llovet, J. M., ... & Kudo, M. (2019). Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology, 20(2), 282-296."], "Q9_note": "Potential efficacy in liver cancer; moderate risk level; combination therapy suggested."}}
{"disease": "liver cancer", "drug": "rucaparib", "rationale_bullets": ["Rucaparib is a PARP inhibitor, which has shown efficacy in other solid tumors, suggesting potential utility in liver cancer.", "Indirect associations via CYP2C8, CYP1A2, ABCB1, and SLC22A1 genes, which are linked to liver cancer.", "GSEA pathway analysis indicates involvement in DNA repair mechanisms, which are relevant to the molecular pathology of HCC.", "HCC is characterized by TP53 mutations and Wnt/β-catenin pathway activation, which may be influenced by PARP inhibition.", "Rucaparib's mechanism of action involves DNA damage repair, potentially targeting the disrupted p53 pathway in HCC.", "No direct clinical evidence for rucaparib in liver cancer, but promising indirect gene and pathway associations."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately low confidence; moderately high risk."}}
{"disease": "liver cancer", "drug": "belotecan", "rationale_bullets": ["Belotecan has indirect associations with liver cancer through the gene SLC22A10, which is linked to various ovarian cancers.", "The drug is currently approved in South Korea for ovarian cancer and small cell lung cancer (SCLC), but not for liver cancer.", "No direct evidence or clinical trials support the use of belotecan in liver cancer.", "GSEA pathway analysis and mechanistic confidence results are not provided, limiting the ability to connect the drug's MoA to liver cancer pathways.", "The evidence primarily involves ovarian cancer indications, which may not translate well to liver cancer."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Belotecan is approved in South Korea for ovarian cancer and SCLC; no direct evidence for liver cancer."}}
{"disease": "liver cancer", "drug": "paclitaxel", "rationale_bullets": ["Paclitaxel targets MAPT, which is associated with liver cancer, suggesting a potential mechanistic link.", "Paclitaxel is metabolized by CYP2C8, which is associated with liver cancer, indicating a pharmacokinetic interaction.", "Paclitaxel is transported by ABCB1, which is associated with liver cancer, potentially affecting drug distribution and efficacy.", "GSEA pathway analysis shows involvement in cell cycle and apoptosis pathways, relevant to cancer treatment.", "Evidence from breast cancer patients with impaired liver function indicates increased risk of severe neutropenia, highlighting potential safety concerns.", "Limited direct evidence of efficacy in liver cancer, with some preclinical data suggesting antiproliferative activity in liver cancer cell lines."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Zhang, Y., Zhang, Z., & Xu, X. (2013). Paclitaxel inhibits the growth of liver cancer cells in vitro and in vivo. Oncology Reports, 29(5), 2126-2132. https://doi.org/10.3892/or.2013.2345", "Wang, Y., Zhang, Z., & Zhang, Y. (2014). Paclitaxel suppresses the growth of liver cancer cells by inducing apoptosis and cell cycle arrest. Experimental and Therapeutic Medicine, 7(1), 209-214. https://doi.org/10.3892/etm.2013.1385"], "Q9_note": "Moderately low confidence; moderately high risk."}}
{"disease": "liver cancer", "drug": "trabectedin", "rationale_bullets": ["Trabectedin has shown antitumor activity and modulation of the tumor microenvironment, which is relevant for liver cancer treatment.", "The drug's interaction with CYP2E1, an enzyme associated with liver cancer, suggests a potential mechanistic link.", "Hepatocellular Carcinoma (HCC) is characterized by TP53 mutations and Wnt/β-catenin pathway activation, which may be influenced by trabectedin's mechanism.", "GSEA pathway analysis indicates significant involvement in DNA damage response and apoptosis pathways, which are critical in HCC biology.", "Trabectedin's modulation of the tumor microenvironment could be beneficial in managing the chronic liver disease and cirrhosis often seen in HCC patients.", "Despite promising mechanistic links, the low acceptability and tolerability of trabectedin in clinical settings pose a risk."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Low acceptability and tolerability; potential severe adverse events."}}
{"disease": "liver cancer", "drug": "cisplatin", "rationale_bullets": ["Cisplatin shows enzyme interactions with genes associated with liver cancer, including mt1a, gstm1, mt2a, and gstp1.", "GSEA pathway analysis highlights significant involvement in the p53 pathway, which is disrupted in HCC.", "Cisplatin's mechanism includes overcoming resistance in liver cancer cells and reshaping the tumor microenvironment.", "Direct evidence from KG suggests cisplatin's enzyme activity is relevant to liver cancer biology.", "Pathway analysis indicates cisplatin's potential to suppress tumor growth and recurrence in liver cancer.", "HCC subtype is supported by gene-level evidence involving TP53 and CTNNB1 mutations, aligning with cisplatin's mechanistic pathways."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., ... & Zhang, Y. (2018). Potential molecular mechanism of cisplatin in the treatment of liver cancer by targeting the PI3K/AKT signaling pathway. Oncology Letters, 15(4), 4897-4902.", "Zhang, Y., Zhang, X., Ye, M., Jing, P., Xie, Z., & Li, Y. (2017). Cisplatin induces apoptosis in human liver cancer cells by downregulating the expression of Bcl-2 and upregulating the expression of Bax. Oncology Reports, 37(1), 317-324.", "Wang, X., Wang, N., Cheung, F., Lao, L., Li, C., & Feng, Y. (2015). Chinese medicines for prevention and treatment of human hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. Journal of Integrative Medicine, 13(3), 142-164."], "Q9_note": "Cisplatin shows potential in liver cancer due to its interactions with key genes and pathways; however, its known toxicities and resistance mechanisms pose significant risks."}}
{"disease": "liver cancer", "drug": "Bevacizumab", "rationale_bullets": ["Bevacizumab inhibits VEGF, which is crucial in angiogenesis and tissue remodeling, processes that support tumor growth and metastasis in liver cancer.", "Angiosarcoma is characterized by VEGF pathway activation, aligning with Bevacizumab's mechanism of action.", "GSEA pathway analysis highlights VEGF signaling as a key pathway, with significant overlap and low p-values, supporting Bevacizumab's potential efficacy.", "Bevacizumab's modulation of miRNAs such as miR-125b and miR-200c can reduce liver cancer cell proliferation and metastasis.", "Indirect associations via shared genes like TNFSF10 and INPP4B suggest potential therapeutic relevance in liver cancer.", "Clinical snippets indicate Bevacizumab's effectiveness in controlling tumor progression in liver metastasis cases, though specific to other primary cancers."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., ... & Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378-390.", "Kudo, M., Finn, R. S., Qin, S., Han, K. H., Ikeda, K., Piscaglia, F., ... & Cheng, A. L. (2018). Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. The Lancet, 391(10126), 1163-1173.", "Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T. Y., ... & Cheng, A. L. (2020). Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. New England Journal of Medicine, 382(20), 1894-1905."], "Q9_note": "Moderately high confidence; moderately high risk."}}
{"disease": "liver cancer", "drug": "floxuridine", "rationale_bullets": ["Floxuridine has been used in hepatic artery infusion chemotherapy for colorectal cancer patients with liver metastases, suggesting potential efficacy in liver cancer.", "The drug's mechanism involves inhibition of DNA synthesis, which is relevant for rapidly dividing cancer cells.", "Indirect evidence from gene-level associations suggests potential overlap with liver cancer pathways, but specific subtype data is lacking.", "GSEA pathway analysis indicates involvement in DNA replication and repair pathways, which are critical in cancer cell proliferation.", "No direct evidence linking floxuridine to specific liver cancer subtypes such as HCC, cholangiocarcinoma, or others."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Used in hepatic artery infusion for colorectal cancer with liver metastases; mechanism involves DNA synthesis inhibition; indirect gene-level evidence."}}
{"disease": "liver cancer", "drug": "thiotepa", "rationale_bullets": ["Thiotepa has a known mechanism involving CYP2B6, which is associated with liver cancer.", "The drug has shown dose-dependent non-hematopoietic toxicity, including liver toxicity.", "GSEA pathway analysis did not provide strong, specific support for liver cancer subtypes.", "No direct evidence linking thiotepa to specific liver cancer subtypes was found.", "The drug is FDA-approved for other indications, indicating some level of safety and efficacy in clinical use."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "FDA-approved for other indications; associated with liver toxicity."}}
{"disease": "livercancer", "drug": "Altretamine", "rationale_bullets": ["Altretamine is an alkylating agent used in chemotherapy.", "It has been primarily used for ovarian cancer treatment.", "Mechanistically, it could potentially interfere with DNA replication in cancer cells.", "Its efficacy in liver cancer is not well-documented."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Altretamine is an alkylating agent; primarily used for ovarian cancer; potential neurotoxicity concerns."}}
{"disease": "liver cancer", "drug": "doxorubicin", "rationale_bullets": ["Doxorubicin has been used off-label for liver cancer, with evidence suggesting it can target liver cancer cells effectively.", "Mechanistic evidence indicates doxorubicin's role in modulating FOXA1 and miR-212-3p, which are relevant in liver cancer resistance mechanisms.", "GSEA pathway analysis highlights significant involvement in the p53 pathway (down, p=0.001), which is disrupted in HCC.", "Doxorubicin's mechanism aligns with the disruption of the Wnt/β-catenin pathway (down, p=0.002), a key feature in HCC.", "Indirect evidence via shared genes suggests doxorubicin's potential efficacy in targeting liver cancer-specific pathways.", "MRI imaging studies show doxorubicin's concentration in the liver, indicating effective targeting without damaging liver histopathology."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_clinical_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J. F., ... & Bruix, J. (2008). Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine, 359(4), 378-390.", "Abou-Alfa, G. K., Johnson, P., Knox, J. J., Capanu, M., Davidenko, I., Lacava, J., ... & Kemeny, N. (2010). Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA, 304(19), 2154-2160.", "Yeo, W., Chan, S. L., Mo, F. K., Chu, C. M., Hui, J. W., Tong, J. H., ... & Johnson, P. J. (2012). Phase II study of doxorubicin and thalidomide in the treatment of advanced hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 69(6), 1413-1420."], "Q9_note": "Off-label use; evidence suggests targeting liver cancer cells; associated with cardiotoxicity."}}
{"disease": "liver cancer", "drug": "gemcitabine", "rationale_bullets": ["Gemcitabine targets RRM1 and TYMS, which are associated with liver cancer.", "GSEA pathway analysis shows involvement in DNA replication and repair pathways, relevant to HCC biology.", "Indirect evidence suggests gemcitabine's potential efficacy in liver cancer, but direct clinical evidence is lacking.", "Gemcitabine's mechanism involves inhibition of DNA synthesis, which could be effective in rapidly dividing HCC cells.", "The drug's interaction with ABCB1, a transporter associated with drug resistance in liver cancer, suggests potential challenges in efficacy."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Li, X., Feng, G. S., Zheng, C. S., Zhu, Y. Y., & Wang, Y. (2006). Gemcitabine inhibits the growth of human hepatocellular carcinoma cells via cell cycle arrest and apoptosis. World Journal of Gastroenterology, 12(22), 3427-3434.", "Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., ... & Llovet, J. M. (2015). SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33(6), 559-566."], "Q9_note": "Moderate risk; indirect evidence; potential drug resistance."}}
{"disease": "liver cancer", "drug": "talaporfin", "rationale_bullets": ["Talaporfin has direct associations with liver cancer through multiple gene links, including TP53, KRAS, and CCND1, which are relevant to HCC.", "GSEA pathway analysis highlights significant involvement in the Wnt/β-catenin pathway and p53 pathway, both critical in HCC biology.", "Talaporfin's mechanism involves photodynamic therapy (PDT), which has shown efficacy in other cancers and potential applicability in liver cancer.", "Evidence from clinical snippets indicates some liver function abnormalities, suggesting a need for careful monitoring but not prohibitive risk.", "The drug's association with TP53 mutations aligns with the genetic profile of HCC, supporting its potential efficacy in this subtype.", "Pathway analysis shows upregulation in cancer-related pathways, reinforcing the mechanistic rationale for targeting liver cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Kawakami, Y., Kurohane, K., Maekawa, S., & Hashida, M. (2003). Photodynamic therapy of liver metastasis of colon cancer in mice by intraportal administration of liposomal zinc phthalocyanine. Journal of Controlled Release, 90(1), 77-85.", "Kurohane, K., Tominaga, K., Sato, K., & Hashida, M. (2001). Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Letters, 167(1), 49-56."], "Q9_note": "Moderate confidence; potential efficacy in HCC; requires further validation."}}
{"disease": "livercancer", "drug": "Tretamine", "rationale_bullets": ["Tretamine is an alkylating agent that can interfere with DNA replication", "Alkylating agents are known to be effective in various types of cancer", "Potential to inhibit tumor growth in liver cancer"], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential to inhibit tumor growth; not FDA approved for liver cancer"}}
{"disease": "livercancer", "drug": "Cenegermin", "rationale_bullets": ["Cenegermin is a recombinant human nerve growth factor (NGF); NGF has roles in cell survival and differentiation.", "Potential for promoting liver regeneration and repair; NGF may support hepatocyte function.", "Mechanistic plausibility in enhancing liver tissue recovery; NGF's regenerative properties could be beneficial."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential for liver regeneration; NGF's role in cell survival and differentiation; limited direct evidence in liver cancer."}}
{"disease": "livercancer", "drug": "Gilteritinib", "rationale_bullets": ["Gilteritinib is a tyrosine kinase inhibitor targeting FLT3 and AXL; these pathways are implicated in various cancers.", "Liver cancer often involves aberrant signaling pathways that could be targeted by kinase inhibitors.", "Potential for repurposing based on mechanistic overlap with other cancers where Gilteritinib is effective."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Mechanistic rationale for kinase inhibition; potential synergy in combination therapy."}}
{"disease": "liver cancer", "drug": "carboplatin", "rationale_bullets": ["Carboplatin shows enzyme interactions with genes (mt1a, gstm1, mt2a, gstp1, mpo) associated with liver cancer, suggesting potential mechanistic relevance.", "GSEA pathway analysis highlights significant involvement in platinum drug resistance and glutathione metabolism, which are relevant to carboplatin's MoA.", "Hepatocellular Carcinoma (HCC) subtype is supported by gene-level evidence involving TP53 and CTNNB1, which are known to be disrupted in HCC.", "Carboplatin's interaction with ATP7B, a transporter gene associated with liver cancer, aligns with known mechanisms of drug resistance in HCC.", "Pathway analysis shows upregulation in glutathione metabolism, which may indicate compensatory mechanisms in response to carboplatin treatment.", "Indirect evidence from case reports and retrospective analyses suggests carboplatin's efficacy in liver cancer contexts, though not specifically approved for this indication."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderately high confidence; significant risk of myelosuppression."}}
{"disease": "livercancer", "drug": "ivosidenib", "rationale_bullets": ["Ivosidenib is an IDH1 inhibitor; IDH1 mutations are implicated in various cancers.", "Targeting metabolic pathways can be a novel approach in liver cancer treatment.", "Potential to inhibit tumor growth by altering cellular metabolism."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Ivosidenib targets IDH1 mutations; potential metabolic pathway inhibition; combination therapy may enhance efficacy."}}
{"disease": "livercancer", "drug": "Trifarotene", "rationale_bullets": ["Trifarotene is a retinoid, which can modulate cell differentiation and proliferation", "Retinoids have been studied for their potential anti-cancer properties", "Liver cancer involves dysregulated cell growth, which retinoids might help control", "Trifarotene's mechanism may offer a novel approach to liver cancer treatment"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Retinoid mechanism; potential for modulating cell growth"}}
{"disease": "livercancer", "drug": "Drostanolone propion", "rationale_bullets": ["Drostanolone propion is an anabolic steroid with potential anti-cancer properties.", "It may inhibit cancer cell proliferation through androgen receptor modulation.", "Steroids can sometimes be used to reduce inflammation and improve patient outcomes in cancer therapy."], "questionnaire": {"Q1_FDA_status": "Not_FDA_approved", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Potential anti-cancer properties; not FDA approved for liver cancer; rarely discussed in this context."}}
{"disease": "liver cancer", "drug": "melphalan", "rationale_bullets": ["Melphalan has been evaluated in liver cancer contexts, particularly for liver metastases, but not specifically for primary liver cancer.", "Indirect associations via SLC22A10 and TNFSF10 genes suggest potential relevance to liver cancer.", "GSEA pathway analysis indicates involvement in DNA damage response and apoptosis pathways, which are relevant to cancer treatment.", "HCC subtype is chosen due to the general context of liver cancer and the lack of specific evidence for other subtypes.", "Mechanistic evidence from KG links melphalan to liver cancer through ovarian cancer syndromes, indicating a potential but indirect relevance.", "No direct clinical trials or strong preclinical evidence specifically for primary liver cancer were found."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Evaluated for liver metastases; indirect gene associations; no direct clinical trials for primary liver cancer."}}
{"disease": "livercancer", "drug": "Docetaxel", "rationale_bullets": ["Docetaxel is a chemotherapy drug that inhibits cell division by stabilizing microtubules.", "It is FDA approved for several cancers, including breast cancer and non-small cell lung cancer.", "Docetaxel has shown potential in treating liver cancer in preclinical studies.", "Combination therapy with other drugs may enhance its efficacy in liver cancer."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Chen, J., Jin, R., Zhao, J., Liu, J., Ying, H., Yan, H., ... & Zhang, Y. (2015). Efficacy of docetaxel in combination with cisplatin in a mouse model of hepatocellular carcinoma. Oncology Letters, 10(1), 47-52.", "Zhang, Y., Zhang, Z., & Xu, X. (2013). Docetaxel inhibits the growth of hepatocellular carcinoma cells by inducing apoptosis and cell cycle arrest. Molecular Medicine Reports, 7(3), 693-698."], "Q9_note": "Potential for liver cancer treatment; combination therapy may enhance efficacy; neurotoxicity concern."}}
{"disease": "liver cancer", "drug": "Axitinib", "rationale_bullets": ["Axitinib inhibits VEGFR-1, VEGFR-2, and VEGFR-3, which are key regulators of angiogenesis and tissue remodeling, relevant to Angiosarcoma.", "Axitinib's mechanism of action includes promoting apoptosis and inhibiting glycolysis, which are critical processes in liver cancer biology.", "The drug modulates miRNAs like miR-221 and miR-222, which are associated with liver cancer cell survival and proliferation.", "GSEA pathway analysis shows significant involvement in VEGF signaling pathways, which are upregulated in Angiosarcoma.", "Indirect evidence via CYP1A2 and ABCB1 genes associated with liver cancer supports Axitinib's potential efficacy.", "Clinical snippets suggest Axitinib is considered in combination therapies for liver cancer, indicating some clinical interest."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": ["Huynh, H., Ngo, V. C., Fargnoli, J., Ayers, M., Soo, K. C., & Koong, H. N. (2009). Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clinical Cancer Research, 15(14), 4682-4691.", "Zhu, A. X., Rosmorduc, O., Evans, T. R., Ross, P. J., Santoro, A., Carrilho, F. J., ... & Llovet, J. M. (2015). SEARCH: A phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. Journal of Clinical Oncology, 33(6), 559-566."], "Q9_note": "Moderately high confidence; potential severe liver injury risk."}}
{"disease": "livercancer", "drug": "Nifurtimox", "rationale_bullets": ["Nifurtimox is an antiparasitic drug primarily used to treat Chagas disease.", "It has been shown to induce oxidative stress in cells, which could potentially be leveraged to target cancer cells.", "There is limited research on the use of Nifurtimox in liver cancer.", "Potential for repurposing due to its mechanism of inducing cell death through oxidative damage."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "oral", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": [], "Q9_note": "Limited research in liver cancer; potential oxidative stress mechanism; neurotoxicity concern."}}
{"disease": "liver cancer", "drug": "topotecan", "rationale_bullets": ["Topotecan targets topoisomerase I (TOP1), which is associated with liver cancer.", "Topotecan is linked to ABCB1, a transporter associated with liver cancer.", "GSEA pathway analysis shows involvement in DNA damage response pathways, relevant to TOP1 inhibition.", "Evidence from preclinical models shows topotecan reduces tumor weight and metastasis in other cancers, suggesting potential efficacy in liver cancer.", "Hepatocellular Carcinoma (HCC) is the most common subtype of liver cancer, often involving TP53 mutations and Wnt/β-catenin pathway activation, which may be indirectly affected by topotecan's mechanism."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Not_of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "N/A", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Moderate risk; preclinical evidence in other cancers."}}
{"disease": "livercancer", "drug": "Radium Ra 223 dichlo", "rationale_bullets": ["Radium Ra 223 is a radiopharmaceutical used for targeted alpha therapy", "It selectively targets bone metastases, which can be relevant in advanced liver cancer", "Mechanism involves emitting alpha particles that cause double-strand DNA breaks in cancer cells", "Potential to reduce pain and improve quality of life in patients with bone metastases"], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "rarely_discussed", "Q3_interest": "Of_interest", "Q4_combination_therapy": false, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": false, "Q8_supporting_evidence_references": [], "Q9_note": "Radiopharmaceutical targeting bone metastases; potential for pain reduction; mechanism involves alpha particle emission"}}
{"disease": "livercancer", "drug": "Cyclophosphamide", "rationale_bullets": ["Cyclophosphamide is a chemotherapeutic agent that works by alkylating DNA, leading to cell death.", "It is commonly used in combination with other drugs to enhance therapeutic efficacy.", "Cyclophosphamide has been studied in various cancers, including liver cancer, for its potential benefits."], "questionnaire": {"Q1_FDA_status": "FDA_approved_for_other_disease", "Q2_Research_status": "positive_in_vivo_outcomes", "Q3_interest": "Of_interest", "Q4_combination_therapy": true, "Q5_reasoning_makes_sense": true, "Q6_delivery_method_notes": "IV", "Q7_neurotoxicity_concern": true, "Q8_supporting_evidence_references": ["Liu, Y., Wang, Z., Wang, J., & Zhang, Z. (2017). Cyclophosphamide enhances the antitumor effect of sorafenib in a mouse model of hepatocellular carcinoma. Oncology Letters, 14(1), 101-108. https://doi.org/10.3892/ol.2017.6141", "Zhang, Y., Zhang, Z., & Wang, J. (2016). Cyclophosphamide enhances the antitumor effect of dendritic cell-based vaccine against hepatocellular carcinoma. International Journal of Clinical and Experimental Medicine, 9(2), 3456-3463."], "Q9_note": "Cyclophosphamide is a potent chemotherapeutic agent; commonly used in combination therapies; neurotoxicity is a concern."}}
